Disease Domain | Count |
---|---|
Infectious Diseases | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Microbiota | 1 |
Top 5 Target | Count |
---|---|
PE-PGRS(Mycobacterium tuberculosis PE-PGRS protein) | 3 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PE-PGRS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PE-PGRS inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date10 Feb 2024 |
Sponsor / Collaborator |
Start Date17 Aug 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Lactobarriome 5% Cream | Pruritus More | Phase 1/2 |
PP1S ( PE-PGRS ) | Tuberculosis More | Preclinical |
PP2S ( PE-PGRS ) | Tuberculosis More | Preclinical |
PP3S ( PE-PGRS ) | Tuberculosis More | Preclinical |